Jump to navigation

Draft pandemic treaty could force Big Pharma to share vaccines with developing countries

Major battles lie ahead as negotiations on a new treaty to set rules for production and distribution of life-saving drugs

Negotiations on protocols for a global and national level pandemic response have started with the World Health Organization's (WHO) Intergovernmental Negotiating Body's (INB) publication of a 'zero-draft' of a new pandemic treaty last week.

The draft states that the WHO is 'deeply concerned by the gross inequities' of supply, production and access to Covid-19 vaccines. Its proposal to reserve at least 20% of any tests, vaccines or treatments for use in poorer countries is likely to prompt major pushback from pharmaceutical giants.

Civil society groups say the treaty should compel governments to commit to sharing medical technology and knowhow. It also states that the intellectual property rules that uphold pharmaceutical company monopolies must be waived automatically when a health emergency is declared.

This points to the need for clear enforcement of the treaty which raises another raft of diplomatic questions. The WHO insists the treaty should be legally binding.

The draft cites the backdrop to its recommendations as the 'catastrophic failure of the international community in showing solidarity and equity in response to the novel Covid-19 pandemic'. The final draft is set to be presented at the World Health Assembly in 2024.

Other proposals in the draft include strengthening and sustaining capacities of health systems, cooperation for sustainable and predictable financing, and raising pandemic and public health literacy for pandemic prevention, preparedness, response and recovery.

It also calls for the establishment of the WHO Global Pandemic Supply Chain and Logistics Network to promote production and transfer of technology and know-how.

This network would boost research and development capacities and establish a Pathogen Access Benefit-Sharing System (PABS) to ensure equitable and timely sharing of pathogens with pandemic potential and genomic sequences.



Related Articles

After the pandemic panic, Big Pharma exits Africa

Moderna's mothballing of a $200m vaccine plant has prompted a backlash from politicians and health professionals

When United States' pharmaceutical giant Moderna halted plans for a US$200 million vaccine factory near Nairobi it dealt a double-blow: to Kenya's ambitions as a healthcare manufa...


Time to re-open

Africa’s lockdown era is nearing the end as policy-makers focus on how to live with Covid-19 rather than defeat it

The shadow-boxing over Covid-19 in Africa appears to be over. While retaining measures to protect public health wherever possible, the priority is now shifting to opening up econom...


Third wave threatens the continent

Lack of international consensus on the response to the virus multiplies risks to Africa's economies and healthcare

Top African and UN officials are desperately lobbying a divided international system for a US$100 billion emergency fund to combat what they fear will be a third wave of the corona...


Heroes and villains in the pandemic

The coronavirus outbreak has turned the spotlight on those in charge, highlighting successes and exposing deficiencies

With South Africa in the third week of a lockdown that may only be lifted at the end of April, and possibly not even then, President Cyril Ramaphosa and Health Minister Zweli Mkhiz...


The dearth of data

The pandemic is spreading unevenly across Africa and officials warn of a growing number of hotspots threatening public health

When Kenyan President Uhuru Kenyatta addressed the nation on 4 June, he outlined a dilemma facing many governments. The scientists were telling him to maintain the lockdown while t...